Masafumi Fukagawa mostly deals with Internal medicine, Endocrinology, Parathyroid hormone, Secondary hyperparathyroidism and Hyperparathyroidism. Internal medicine is frequently linked to Urology in his study. The various areas that Masafumi Fukagawa examines in his Endocrinology study include Osteoblast and Fibroblast growth factor 23.
His research in Parathyroid hormone intersects with topics in Downregulation and upregulation, Protein kinase A, Uremia and Hazard ratio. Masafumi Fukagawa interconnects Calcitriol, Parathyroid hormone secretion, Parathyroid gland and Calcium-sensing receptor in the investigation of issues within Secondary hyperparathyroidism. His Hyperparathyroidism research integrates issues from Parathyroidectomy, Cinacalcet, Hyperplasia and Calcification.
Masafumi Fukagawa mostly deals with Internal medicine, Endocrinology, Secondary hyperparathyroidism, Parathyroid hormone and Kidney disease. His research brings together the fields of Gastroenterology and Internal medicine. His Endocrinology research includes themes of Calcium and Fibroblast growth factor 23.
His studies in Secondary hyperparathyroidism integrate themes in fields like Parathyroidectomy, Parathyroid gland and Urology. His work carried out in the field of Parathyroid hormone brings together such families of science as Calcium metabolism, Primary hyperparathyroidism and Uremia. His research investigates the connection between Kidney disease and topics such as Renal function that intersect with problems in Creatinine.
The scientist’s investigation covers issues in Internal medicine, Hemodialysis, Endocrinology, Kidney disease and Secondary hyperparathyroidism. His research on Internal medicine often connects related topics like Gastroenterology. His Hemodialysis research incorporates themes from Calcium, Urology, Mortality rate, Prospective cohort study and Practice patterns.
His study on Endocrinology is mostly dedicated to connecting different topics, such as Fibroblast growth factor 23. His Kidney disease research is multidisciplinary, incorporating perspectives in Bone disease, Osteoporosis, Bone remodeling and Renal function. His Secondary hyperparathyroidism study is concerned with the larger field of Parathyroid hormone.
Masafumi Fukagawa spends much of his time researching Internal medicine, Secondary hyperparathyroidism, Kidney disease, Hemodialysis and Parathyroid hormone. He has included themes like Gastroenterology and Endocrinology in his Internal medicine study. His work focuses on many connections between Endocrinology and other disciplines, such as Fibroblast growth factor 23, that overlap with his field of interest in Anemia and Erythropoietin.
The study incorporates disciplines such as Hyperparathyroidism, Pharmacodynamics and Urology in addition to Secondary hyperparathyroidism. The Kidney disease study combines topics in areas such as Randomized controlled trial, Osteoporosis, Pathology and Bone remodeling. The Hemodialysis study which covers Placebo that intersects with Calcium metabolism and Interquartile range.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients.
N Fukuda;H Tanaka;Y Tominaga;M Fukagawa.
Journal of Clinical Investigation (1993)
Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters
Markus Ketteler;Geoffrey A. Block;Pieter Evenepoel;Masafumi Fukagawa.
Kidney International (2017)
Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.
Takashi Shigematsu;Junichiro James Kazama;Takeyoshi Yamashita;Seiji Fukumoto.
American Journal of Kidney Diseases (2004)
Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients
Hirotaka Komaba;Shunsuke Goto;Hideki Fujii;Yasuhiro Hamada.
Kidney International (2010)
p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase
Hiroshi Watanabe;Yohei Miyamoto;Daisuke Honda;Hisae Tanaka.
Kidney International (2013)
Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients
Shohei Nakanishi;Junichiro James Kazama;Tomoko Nii-Kono;Kentaro Omori.
Kidney International (2005)
Clinical Practice Guideline for the Management of Chronic Kidney Disease‐Mineral and Bone Disorder
Masafumi Fukagawa;Keitaro Yokoyama;Fumihiko Koiwa;Masatomo Taniguchi.
Therapeutic Apheresis and Dialysis (2013)
Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients.
Masafumi Fukagawa;Masafumi Kitaoka;Hung Yi;Naoko Fukuda.
Cloning and characterization of developmental endothelial locus-1: An embryonic endothelial cell protein that binds the αvβ3 integrin receptor
Chiaki Hidai;Thomas Zupancic;Kalyani Penta;Kalyani Penta;Adel Mikhail.
Genes & Development (1998)
Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy.
Kevin J Martin;Klaus Olgaard;Jack W Coburn;Jack W Coburn;Giorgio M Coen;Giorgio M Coen.
American Journal of Kidney Diseases (2004)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: